{"title":"油橄榄果实生物活性成分减轻缺氧诱导细胞损伤的正交化学生物学分析","authors":"Chengfu Zhang , Jiangjuan Yuan , Xia Zhang , Wenjin Ma , Dong Pei , Lansheng Zhang , Lichun Zhao , Qingli Qu","doi":"10.1016/j.jpba.2025.117167","DOIUrl":null,"url":null,"abstract":"<div><div>Hypoxic stress, a pathological hallmark of cardiovascular, oncological, and neurodegenerative diseases, underscores the need for safer hypoxia-targeting therapeutics beyond conventional agents with dose-limiting toxicities. The protective effect of polyphenols from <em>Olea europaea</em> L. fruit (<em>OEL</em>-F) against hypoxic injury in PC12 cells was investigated in this study. Furthermore, the main bioactive components responsible for this protective effect were isolated and characterized. An integrated chemometrics approach facilitated the systematic identification of 23 characteristic markers through HPLC analysis of 17 OEL-F extracts. Coupling with CoCl₂-induced hypoxia modelling in PC12 cells (cell viability assessed <em>via</em> MTT assay) and orthogonal biological validation to identify five hypoxia-alleviating bioactive markers precisely. S6 extract demonstrated significantly superior biological activity in the repair of hypoxic injury compared to all other groups (<em>p</em> < 0.01). Bioactivity-directed fractionation led to the identification of luteolin-4′-O-β-D-glucoside and oleuropein as primary bioactive constituents. Molecular docking analysis indicated that these compounds exhibit structural motifs analogous to vadadustat (a clinical PHD2 inhibitor), engaging residues His313/Tyr310 in the substrate pocket. Unlike vadadustat's Fe²⁺-chelating mechanism, these constituents act as potential competitive PHD2 inhibitors via non-chelating interactions at the catalytic site. Molecular docking suggests that <em>OEL</em>-F polyphenols may stabilize HIF-1α through PHD2 inhibition, proposing a novel natural product-driven strategy for safer hypoxia intervention.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"267 ","pages":"Article 117167"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Orthogonal chemical-biological profiling of bioactive components from Olea europaea L. fruits for mitigating hypoxia-induced cellular injury\",\"authors\":\"Chengfu Zhang , Jiangjuan Yuan , Xia Zhang , Wenjin Ma , Dong Pei , Lansheng Zhang , Lichun Zhao , Qingli Qu\",\"doi\":\"10.1016/j.jpba.2025.117167\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Hypoxic stress, a pathological hallmark of cardiovascular, oncological, and neurodegenerative diseases, underscores the need for safer hypoxia-targeting therapeutics beyond conventional agents with dose-limiting toxicities. The protective effect of polyphenols from <em>Olea europaea</em> L. fruit (<em>OEL</em>-F) against hypoxic injury in PC12 cells was investigated in this study. Furthermore, the main bioactive components responsible for this protective effect were isolated and characterized. An integrated chemometrics approach facilitated the systematic identification of 23 characteristic markers through HPLC analysis of 17 OEL-F extracts. Coupling with CoCl₂-induced hypoxia modelling in PC12 cells (cell viability assessed <em>via</em> MTT assay) and orthogonal biological validation to identify five hypoxia-alleviating bioactive markers precisely. S6 extract demonstrated significantly superior biological activity in the repair of hypoxic injury compared to all other groups (<em>p</em> < 0.01). Bioactivity-directed fractionation led to the identification of luteolin-4′-O-β-D-glucoside and oleuropein as primary bioactive constituents. Molecular docking analysis indicated that these compounds exhibit structural motifs analogous to vadadustat (a clinical PHD2 inhibitor), engaging residues His313/Tyr310 in the substrate pocket. Unlike vadadustat's Fe²⁺-chelating mechanism, these constituents act as potential competitive PHD2 inhibitors via non-chelating interactions at the catalytic site. Molecular docking suggests that <em>OEL</em>-F polyphenols may stabilize HIF-1α through PHD2 inhibition, proposing a novel natural product-driven strategy for safer hypoxia intervention.</div></div>\",\"PeriodicalId\":16685,\"journal\":{\"name\":\"Journal of pharmaceutical and biomedical analysis\",\"volume\":\"267 \",\"pages\":\"Article 117167\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmaceutical and biomedical analysis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0731708525005084\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, ANALYTICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical and biomedical analysis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0731708525005084","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0
摘要
低氧应激是心血管、肿瘤和神经退行性疾病的病理标志,它强调了在具有剂量限制毒性的传统药物之外,需要更安全的低氧靶向治疗。研究了油橄榄果实多酚对PC12细胞缺氧损伤的保护作用。此外,还分离并鉴定了产生这种保护作用的主要生物活性成分。采用综合化学计量学方法,通过高效液相色谱分析,系统鉴定了23个特征标记。结合CoCl 2诱导的PC12细胞缺氧模型(通过MTT法评估细胞活力)和正交生物学验证,精确鉴定出5种缓解缺氧的生物活性标记物。与其他各组相比,S6提取物在修复缺氧损伤方面表现出显著优于其他各组的生物活性(p <; 0.01)。生物活性定向分离鉴定木犀草素-4′-O-β- d -葡萄糖苷和橄榄苦苷为主要生物活性成分。分子对接分析表明,这些化合物具有类似于vadadustat(一种临床PHD2抑制剂)的结构基元,与底物口袋中的His313/Tyr310残基结合。与vadadustat的Fe 2 +螯合机制不同,这些成分通过在催化位点的非螯合相互作用作为潜在的竞争性PHD2抑制剂。分子对接表明,OEL-F多酚可能通过抑制PHD2来稳定HIF-1α,为更安全的缺氧干预提供了一种新的天然产物驱动策略。
Orthogonal chemical-biological profiling of bioactive components from Olea europaea L. fruits for mitigating hypoxia-induced cellular injury
Hypoxic stress, a pathological hallmark of cardiovascular, oncological, and neurodegenerative diseases, underscores the need for safer hypoxia-targeting therapeutics beyond conventional agents with dose-limiting toxicities. The protective effect of polyphenols from Olea europaea L. fruit (OEL-F) against hypoxic injury in PC12 cells was investigated in this study. Furthermore, the main bioactive components responsible for this protective effect were isolated and characterized. An integrated chemometrics approach facilitated the systematic identification of 23 characteristic markers through HPLC analysis of 17 OEL-F extracts. Coupling with CoCl₂-induced hypoxia modelling in PC12 cells (cell viability assessed via MTT assay) and orthogonal biological validation to identify five hypoxia-alleviating bioactive markers precisely. S6 extract demonstrated significantly superior biological activity in the repair of hypoxic injury compared to all other groups (p < 0.01). Bioactivity-directed fractionation led to the identification of luteolin-4′-O-β-D-glucoside and oleuropein as primary bioactive constituents. Molecular docking analysis indicated that these compounds exhibit structural motifs analogous to vadadustat (a clinical PHD2 inhibitor), engaging residues His313/Tyr310 in the substrate pocket. Unlike vadadustat's Fe²⁺-chelating mechanism, these constituents act as potential competitive PHD2 inhibitors via non-chelating interactions at the catalytic site. Molecular docking suggests that OEL-F polyphenols may stabilize HIF-1α through PHD2 inhibition, proposing a novel natural product-driven strategy for safer hypoxia intervention.
期刊介绍:
This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focusing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome.
Studies from areas of well established and poorly selective methods, such as UV-VIS spectrophotometry (including derivative and multi-wavelength measurements), basic electroanalytical (potentiometric, polarographic and voltammetric) methods, fluorimetry, flow-injection analysis, etc. are accepted for publication in exceptional cases only, if a unique and substantial advantage over presently known systems is demonstrated. The same applies to the assay of simple drug formulations by any kind of methods and the determination of drugs in biological samples based merely on spiked samples. Drug purity/stability studies should contain information on the structure elucidation of the impurities/degradants.